Skip to content
drillr.ai

ADPT

Adaptive Biotechnologies Corporation

NASDAQ · USHealthcareBiotechnology
$21.86-4.62%

Price as of Jul 20, 2026

ADPT news

Adaptive Biotechnologies Corporation news

A server-rendered, paginated timeline of the latest available company news.

  1. Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

    * Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility * Additional proceeds used to pay for the capped call with a premium of 100% and to repurchase $25 million of common stock to reduce potential dilution * Remaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD business SEATTLE, June 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) toda

    Globe Newswire ·

  2. Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

    SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced its intention to pursue a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses. The company is evaluating strategic and structural alternatives for Immune Medicine to support its growth strategy, capi

    Globe Newswire ·

  3. Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

    * Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility * Additional proceeds used to pay for the capped call with a premium of at least 75% and to repurchase up to $25 million of common stock to reduce potential dilution * Remaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD business SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasd

    Globe Newswire ·

  4. At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

    SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ(®) test for measurable residual disease (MRD) assessment will be included in 33 presentations, including one plenary session and 14 oral presentations, across the American

    Globe Newswire ·

  5. Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

    SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences. * Craig-Hallum 23(rd) Annual Institutional Investor Conference – Minneapolis, MN Hosting 1x1 meetings on Thursday, May 28(th) * William Blair 46(th) Annual Growth S

    Globe Newswire ·